DDInter1553 DDInter1763
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Quetiapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Quetiapine {u} (Compound) upregulates {v} (Gene) AMDHD2
AMDHD2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Quetiapine {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Quetiapine {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Quetiapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Quetiapine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) covaries with {v} (Gene) YRDC
YRDC {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Quetiapine {u} (Compound) upregulates {v} (Gene) AMDHD2
AMDHD2 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Quetiapine {u} (Compound) downregulates {v} (Gene) PPP2R3C
PPP2R3C {u} (Gene) is downregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Quetiapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Quetiapine (Compound) upregulates AMDHD2 (Gene) and AMDHD2 (Gene) is upregulated by Temsirolimus (Compound)
Quetiapine (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is downregulated by Temsirolimus (Compound)
Quetiapine (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Quetiapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Quetiapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) covaries with YRDC (Gene) and YRDC (Gene) is downregulated by Temsirolimus (Compound)
Quetiapine (Compound) upregulates AMDHD2 (Gene) and AMDHD2 (Gene) is upregulated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Quetiapine (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is downregulated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)